107 related articles for article (PubMed ID: 6593484)
21. Stability of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in combination.
Guo D; Myrdal PB; Karlage KL; O'Connell SP; Wissinger TJ; Tabibi SE; Yalkowsky SH
AAPS PharmSciTech; 2010 Mar; 11(1):247-52. PubMed ID: 20151336
[TBL] [Abstract][Full Text] [Related]
22. Comparative studies of the cytostatic action and metabolism of 5-azacytidine and 5,6-dihydro-5-azacytidine.
Voytek P; Beisler JA; Abbasi MM; Wolpert-DeFilippes MK
Cancer Res; 1977 Jul; 37(7 Pt 1):1956-61. PubMed ID: 67884
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice.
Beumer JH; Eiseman JL; Parise RA; Joseph E; Holleran JL; Covey JM; Egorin MJ
Clin Cancer Res; 2006 Dec; 12(24):7483-91. PubMed ID: 17138702
[TBL] [Abstract][Full Text] [Related]
24. Sensitization to X ray by 5-chloro-2'-deoxycytidine co-administered with tetrahydrouridine in several mammalian cell lines and studies of 2'-chloro derivatives.
Perez LM; Greer S
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1523-7. PubMed ID: 3759575
[TBL] [Abstract][Full Text] [Related]
25. Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels.
Funamizu N; Lacy CR; Fujita K; Furukawa K; Misawa T; Yanaga K; Manome Y
PLoS One; 2012; 7(5):e37424. PubMed ID: 22616006
[TBL] [Abstract][Full Text] [Related]
26. Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans.
Holleran JL; Beumer JH; McCormick DL; Johnson WD; Newman EM; Doroshow JH; Kummar S; Covey JM; Davis M; Eiseman JL
Cancer Chemother Pharmacol; 2015 Oct; 76(4):803-11. PubMed ID: 26321472
[TBL] [Abstract][Full Text] [Related]
27. Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.
Beumer JH; Eiseman JL; Parise RA; Florian JA; Joseph E; D'Argenio DZ; Parker RS; Kay B; Covey JM; Egorin MJ
Cancer Chemother Pharmacol; 2008 Aug; 62(3):457-64. PubMed ID: 18008070
[TBL] [Abstract][Full Text] [Related]
28. Incorporation of 5-fluorodeoxycytidine and metabolites into nucleic acids of human MCF-7 breast carcinoma cells.
Kaysen J; Spriggs D; Kufe D
Cancer Res; 1986 Sep; 46(9):4534-8. PubMed ID: 2425957
[TBL] [Abstract][Full Text] [Related]
29. Cytotoxic and biochemical effects of thymidine and 3-deazauridine on human tumor cells.
Lockshin A; Mendoza JT; Giovanella BC; Stehlin JS
Cancer Res; 1984 Jun; 44(6):2534-9. PubMed ID: 6722792
[TBL] [Abstract][Full Text] [Related]
30. Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites.
Besnard T; Renée N; Etienne-Grimaldi MC; François E; Milano G
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jul; 870(1):117-20. PubMed ID: 18562256
[TBL] [Abstract][Full Text] [Related]
31. Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.
Beumer JH; Eiseman JL; Gilbert JA; Holleran JL; Yellow-Duke AE; Clausen DM; D'Argenio DZ; Ames MM; Hershberger PA; Parise RA; Bai L; Covey JM; Egorin MJ
Cancer Chemother Pharmacol; 2011 Feb; 67(2):421-30. PubMed ID: 20443002
[TBL] [Abstract][Full Text] [Related]
32. Deoxycytidine transport in the presence of a cytidine deaminase inhibitor and the transport of uracil in Escherichia coli B.
von Dippe PJ; Leung K; Roy-Burman S; Visser DW
J Biol Chem; 1975 May; 250(10):3666-71. PubMed ID: 1092677
[TBL] [Abstract][Full Text] [Related]
33. Effect of tetrahydrouridine on metabolism and transport of 1-beta-D-arabinofuranosylcytosine in human cells.
Riva C; Barra Y; Carcassonne Y; Cano JP; Rustum Y
Chemotherapy; 1992; 38(5):358-66. PubMed ID: 1286578
[TBL] [Abstract][Full Text] [Related]
34. Epimer interconversion, isomerization, and hydrolysis of tetrahydrouridine: implications for cytidine deaminase inhibition.
Xiang TX; Niemi R; Bummer P; Anderson BD
J Pharm Sci; 2003 Oct; 92(10):2027-39. PubMed ID: 14502542
[TBL] [Abstract][Full Text] [Related]
35. Influence of tetrahydrouridine on the phosphorylation of 1-beta-D-arabinofuranosyl-cytosine (ara-C) by enzymes from solid tumors in vitro.
Furner RL; Mellett LB; Herren TC
J Pharmacol Exp Ther; 1975 Jul; 194(1):103-10. PubMed ID: 1057009
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of deamination of 14C-cytosine arabinoside (NSC-63878): a useful biologic assay for tetrahydrouridine (NSC-112907).
Furner RL; Mellett LB
Cancer Chemother Rep; 1975; 59(4):717-20. PubMed ID: 809135
[TBL] [Abstract][Full Text] [Related]
37. Marked radiosensitization of cells in culture to X ray by 5-chlorodeoxycytidine coadministered with tetrahydrouridine, and inhibitors of pyrimidine biosynthesis.
Perez LM; Mekras JA; Briggle TV; Greer S
Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1453-8. PubMed ID: 6236189
[TBL] [Abstract][Full Text] [Related]
38. Pyrimidine nucleotide metabolism in L5178Y murine leukemia cells: deoxycytidine protection from deoxyguanosine toxicity.
Theiss JC; Morris NR; Fischer GA
Cancer Biochem Biophys; 1976 May; 1(4):211-4. PubMed ID: 987844
[TBL] [Abstract][Full Text] [Related]
39. The effect of inhibition of cytidine deaminase by tetrahydrouridine on the utilization of deoxycytidine and 5-bromodeoxycytidine for deoxyribonucleic acid synthesis.
Cooper GM; Greer S
Mol Pharmacol; 1973 Nov; 9(6):698-703. PubMed ID: 4762631
[No Abstract] [Full Text] [Related]
40. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase.
Laliberté J; Marquez VE; Momparler RL
Cancer Chemother Pharmacol; 1992; 30(1):7-11. PubMed ID: 1375134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
